Cumberland sets ifetroban DMD heart-disease NDA plan after Apotex deal closesNov 10Quarterly updateCumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals plans NDA filing for ifetroban in DMD heart diseaseOct 26Regulatory milestoneCumberland Pharmaceuticals Inc
Cumberland reports top-line Phase 2a results for ifetroban in systemic sclerosisOct 23Clinical readoutCumberland Pharmaceuticals Inc
Cumberland shares DMD and cancer trial data, closes Apotex sale in Q2 updateAug 4Quarterly updateCumberland Pharmaceuticals Inc
Cumberland closes $100 million asset sale to Apotex, keeps rare disease pipelineJul 1Regulatory decisionCumberland Pharmaceuticals Inc